摘要:
Dihydrate of 4-[[9-[(3-cyclopentyloxy-4-methoxy)benzyl]-6,8-dimethylpurin]-2-yl-3-oxypropyl]pyridine N-oxide, drugs containing the same and a compound useful as an intermediate in the production of this dihydrate. Because of having a phosphodiesterase IV inhibitory effect, this dihydrate is useful as a preventive and/or remedy for asthma, chronic obstructive lung disease and/or other inflammatory diseases.
摘要:
A method includes reacting an amino group, a composition including rhodium and an organic ligand, and a substrate having structural formula (I) in a reaction mixture. R1 is an organic group including a sp3 carbon atom bonded to CA. R2 is selected from the group consisting of hydrogen, methyl, and an organic group including a sp3 carbon atom bonded to CA. R3 and R4 independently are selected from the group consisting of hydrogen, methyl, and an organic group including a sp3 carbon atom bonded to CB. The method further includes forming a hydroaminated product in the reaction mixture.
摘要翻译:一种方法包括在反应混合物中使氨基,包含铑和有机配体的组合物和具有结构式(I)的底物反应。 R1是包含与CA键合的sp3碳原子的有机基团。 R2选自氢,甲基和包括与CA结合的sp 3碳原子的有机基团。 R 3和R 4独立地选自氢,甲基和包含与CB结合的sp 3碳原子的有机基团。 所述方法还包括在所述反应混合物中形成聚氨酯产物。
摘要:
A method includes reacting an amino group, a composition including rhodium and an organic ligand, and a substrate having structural formula (I) in a reaction mixture. R1 is an organic group including a sp3 carbon atom bonded to CA. R2 is selected from the group consisting of hydrogen, methyl, and an organic group including a sp3 carbon atom bonded to CA. R3 and R4 independently are selected from the group consisting of hydrogen, methyl, and an organic group including a sp3 carbon atom bonded to CB. The method further includes forming a hydroaminated product in the reaction mixture.
摘要翻译:一种方法包括在反应混合物中使氨基,包含铑和有机配体的组合物和具有结构式(I)的底物反应。 R1是包含与CA键合的sp3碳原子的有机基团。 R2选自氢,甲基和包括与CA结合的sp 3碳原子的有机基团。 R 3和R 4独立地选自氢,甲基和包含与CB结合的sp 3碳原子的有机基团。 所述方法还包括在所述反应混合物中形成聚氨酯产物。
摘要:
The present invention can provide a cancer treatment drug containing, as an active ingredient, a substance selected from the group consisting of an indazole compound of the following formula (I), a pharmaceutically acceptable salt, a hydrate, a water adduct and a solvate:
摘要:
The present invention can provide a cancer treatment drug containing, as an active ingredient, a substance selected from the group consisting of an indazole compound of the following formula (I), a pharmaceutically acceptable salt, a hydrate, a water adduct and a solvate:
摘要:
A compound represented by the following formula (I), or a salt thereof: where X is a halogen atom or a group represented by —S—(CH2)n—A, —SO—(CH2)m—B, —SO2—(CH2)m —B, —OSO2—(CH2)m—B, —OCO—(CH2)m—B or —OPO(OR)—(CH2)m—B, wherein n represents an integer of 0-4, A represents an optionally substituted aromatic hydrocarbon group or an optionally substituted heterocyclic residue having 1 to 4 hetero atoms selected from an oxygen atom, sulfur atom and nitrogen atom and having 5 to 10 ring-constituent atoms, m represents an integer of 0-4, B represents an optionally substituted alkyl group, an optionally substituted aromatic hydrocarbon group or an optionally substituted heterocyclic residue having 1 to 4 hetero atoms selected from an oxygen atom, sulfur atom and nitrogen atom and having 5 to 10 ring-constituent atoms, and R represents an optionally substituted alkyl group.